120 related articles for article (PubMed ID: 32238875)
21. Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.
Paulo P; Ribeiro FR; Santos J; Mesquita D; Almeida M; Barros-Silva JD; Itkonen H; Henrique R; Jerónimo C; Sveen A; Mills IG; Skotheim RI; Lothe RA; Teixeira MR
Neoplasia; 2012 Jul; 14(7):600-11. PubMed ID: 22904677
[TBL] [Abstract][Full Text] [Related]
22. Oncogenic ETS Factors in Prostate Cancer.
Nicholas TR; Strittmatter BG; Hollenhorst PC
Adv Exp Med Biol; 2019; 1210():409-436. PubMed ID: 31900919
[TBL] [Abstract][Full Text] [Related]
23. Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.
Lunardi A; Varmeh S; Chen M; Taulli R; Guarnerio J; Ala U; Seitzer N; Ishikawa T; Carver BS; Hobbs RM; Quarantotti V; Ng C; Berger AH; Nardella C; Poliseno L; Montironi R; Castillo-Martin M; Cordon-Cardo C; Signoretti S; Pandolfi PP
Cancer Discov; 2015 May; 5(5):550-63. PubMed ID: 25653093
[TBL] [Abstract][Full Text] [Related]
24. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.
Kunderfranco P; Mello-Grand M; Cangemi R; Pellini S; Mensah A; Albertini V; Malek A; Chiorino G; Catapano CV; Carbone GM
PLoS One; 2010 May; 5(5):e10547. PubMed ID: 20479932
[TBL] [Abstract][Full Text] [Related]
25. Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication.
Abdelsalam RA; Khalifeh I; Box A; Kalantarian M; Ghosh S; Abou-Ouf H; Lotfi T; Shahait M; Palanisamy N; Bismar TA
J Cancer Res Clin Oncol; 2020 Jul; 146(7):1701-1709. PubMed ID: 32350606
[TBL] [Abstract][Full Text] [Related]
26. Heterogeneity of ERG expression in core needle biopsies of patients with early prostate cancer.
Mertz KD; Horcic M; Hailemariam S; D'Antonio A; Dirnhofer S; Hartmann A; Agaimy A; Eppenberger-Castori S; Obermann E; Cathomas G; Bubendorf L
Hum Pathol; 2013 Dec; 44(12):2727-35. PubMed ID: 24074533
[TBL] [Abstract][Full Text] [Related]
27. Development of High-Throughput Screening Assays for Inhibitors of ETS Transcription Factors.
Currie SL; Warner SL; Vankayalapati H; Liu X; Sharma S; Bearss DJ; Graves BJ
SLAS Discov; 2019 Jan; 24(1):77-85. PubMed ID: 30204534
[TBL] [Abstract][Full Text] [Related]
28. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer.
Mehra R; Tomlins SA; Yu J; Cao X; Wang L; Menon A; Rubin MA; Pienta KJ; Shah RB; Chinnaiyan AM
Cancer Res; 2008 May; 68(10):3584-90. PubMed ID: 18483239
[TBL] [Abstract][Full Text] [Related]
29. Specific and redundant activities of ETV1 and ETV4 in prostate cancer aggressiveness revealed by co-overexpression cellular contexts.
Mesquita D; Barros-Silva JD; Santos J; Skotheim RI; Lothe RA; Paulo P; Teixeira MR
Oncotarget; 2015 Mar; 6(7):5217-36. PubMed ID: 25595908
[TBL] [Abstract][Full Text] [Related]
30. Gene fusion characterisation of rare aggressive prostate cancer variants-adenosquamous carcinoma, pleomorphic giant-cell carcinoma, and sarcomatoid carcinoma: an analysis of 19 cases.
Alhamar M; Tudor Vladislav I; Smith SC; Gao Y; Cheng L; Favazza LA; Alani AM; Ittmann MM; Riddle ND; Whiteley LJ; Gupta NS; Carskadon S; Gomez-Gelvez JC; Chitale DA; Palanisamy N; Hes O; Trpkov K; Williamson SR
Histopathology; 2020 Dec; 77(6):890-899. PubMed ID: 32639612
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of ERG and SPINK1 by Immunohistochemical Staining and Clinicopathological Outcomes in a Multi-Institutional Radical Prostatectomy Cohort of 1067 Patients.
Brooks JD; Wei W; Hawley S; Auman H; Newcomb L; Boyer H; Fazli L; Simko J; Hurtado-Coll A; Troyer DA; Carroll PR; Gleave M; Lance R; Lin DW; Nelson PS; Thompson IM; True LD; Feng Z; McKenney JK
PLoS One; 2015; 10(7):e0132343. PubMed ID: 26172920
[TBL] [Abstract][Full Text] [Related]
32. PTEN and ERG detection in multiparametric magnetic resonance imaging/ultrasound fusion targeted prostate biopsy compared to systematic biopsy.
Baumgartner E; Del Carmen Rodriguez Pena M; Eich ML; Porter KK; Nix JW; Rais-Bahrami S; Gordetsky J
Hum Pathol; 2019 Aug; 90():20-26. PubMed ID: 31075299
[TBL] [Abstract][Full Text] [Related]
33. A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer.
Han B; Mehra R; Dhanasekaran SM; Yu J; Menon A; Lonigro RJ; Wang X; Gong Y; Wang L; Shankar S; Laxman B; Shah RB; Varambally S; Palanisamy N; Tomlins SA; Kumar-Sinha C; Chinnaiyan AM
Cancer Res; 2008 Sep; 68(18):7629-37. PubMed ID: 18794152
[TBL] [Abstract][Full Text] [Related]
34. The peripheral zone of the prostate is more prone to tumor development than the transitional zone: is the ETS family the key?
Adler D; Lindstrot A; Ellinger J; Rogenhofer S; Buettner R; Perner S; Wernert N
Mol Med Rep; 2012 Feb; 5(2):313-6. PubMed ID: 22038307
[TBL] [Abstract][Full Text] [Related]
35. Comparison of ERG and SPINK1 expression among incidental and metastatic prostate cancer in Japanese men.
Koide H; Kimura T; Inaba H; Sato S; Iwatani K; Yorozu T; Furusato B; Kamata Y; Miki J; Kiyota H; Takahashi H; Egawa S
Prostate; 2019 Jan; 79(1):3-8. PubMed ID: 30051483
[TBL] [Abstract][Full Text] [Related]
36. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss.
Chen Y; Chi P; Rockowitz S; Iaquinta PJ; Shamu T; Shukla S; Gao D; Sirota I; Carver BS; Wongvipat J; Scher HI; Zheng D; Sawyers CL
Nat Med; 2013 Aug; 19(8):1023-9. PubMed ID: 23817021
[TBL] [Abstract][Full Text] [Related]
37. Prostate cancer.
Attard G; Parker C; Eeles RA; Schröder F; Tomlins SA; Tannock I; Drake CG; de Bono JS
Lancet; 2016 Jan; 387(10013):70-82. PubMed ID: 26074382
[TBL] [Abstract][Full Text] [Related]
38. TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications.
Barry M; Perner S; Demichelis F; Rubin MA
Urology; 2007 Oct; 70(4):630-3. PubMed ID: 17991527
[TBL] [Abstract][Full Text] [Related]
39. ETS gene aberrations in atypical cribriform lesions of the prostate: Implications for the distinction between intraductal carcinoma of the prostate and cribriform high-grade prostatic intraepithelial neoplasia.
Han B; Suleman K; Wang L; Siddiqui J; Sercia L; Magi-Galluzzi C; Palanisamy N; Chinnaiyan AM; Zhou M; Shah RB
Am J Surg Pathol; 2010 Apr; 34(4):478-85. PubMed ID: 20220513
[TBL] [Abstract][Full Text] [Related]
40. SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort.
Johnson MH; Ross AE; Alshalalfa M; Erho N; Yousefi K; Glavaris S; Fedor H; Han M; Faraj SF; Bezerra SM; Netto G; Partin AW; Trock BJ; Davicioni E; Schaeffer EM
J Urol; 2016 Nov; 196(5):1436-1444. PubMed ID: 27238617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
